Sofregen Medical, Inc.
9
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
22.2%
2 terminated/withdrawn out of 9 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
57%
4 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
Role: lead
Silk Protein Microparticle-based Filler for Injection Augmentation
Role: collaborator
SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair
Role: lead
A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid
Role: lead
SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery
Role: lead
The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe
Role: lead
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery
Role: lead
Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction
Role: lead
SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction
Role: lead
All 9 trials loaded